Douglas Hanahan, Lisa M. Coussens  Cancer Cell 

Slides:



Advertisements
Similar presentations
Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr
Advertisements

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.
Stems Cells and the Pathways to Aging and Cancer
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Cutaneous Cancer Stem Cells: β-Catenin Strikes Again
Volume 7, Issue 3, Pages (March 2005)
Predicting Vaccine Responsiveness
Tumor Dissemination: An EMT Affair
Tumor Microenvironment: No Effector T Cells without Dendritic Cells
Adrienne D. Cox, Kenneth P. Olive  Cancer Cell 
Cancer Immunotherapy by Dendritic Cells
Maša Alečković, Yibin Kang  Cancer Cell 
“Ring-Fencing” BRCA1 Tumor Suppressor Activity
Metastasis gets site specific
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
Genetic Modifiers of the Breast Tumor Microenvironment
Andrew G. Muntean, Jay L. Hess  Cancer Cell 
Tailor-Made Renal Cell Carcinoma Vaccines
“Ring-Fencing” BRCA1 Tumor Suppressor Activity
Deregulating EMT and Senescence: Double Impact by a Single Twist
Volume 26, Issue 1, Pages 1-2 (July 2014)
Figure 1 A schematic representation of the role
A Radical Role for p38 MAPK in Tumor Initiation
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
The AML Salad Bowl Cancer Cell
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Macrophages and Therapeutic Resistance in Cancer
Hallmarks of Cancer: The Next Generation
Macrophages and Therapeutic Resistance in Cancer
Cutaneous Cancer Stem Cells: β-Catenin Strikes Again
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
IL-2: Change Structure … Change Function
Volume 36, Issue 1, Pages 2-14 (October 2009)
Not So Lonely at the Top for Cancer Stem Cells
Mesenchymal Cell Contributions to the Stem Cell Niche
The Hallmarks of Cancer
A New “Brew” of MALT1 Inhibitors
Deregulating EMT and Senescence: Double Impact by a Single Twist
Michael D. Brooks, Monika L. Burness, Max S. Wicha  Cell Stem Cell 
Johan Botling, MD, PhD, Martin Sandelin, MD, PhD 
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
Tumor Self-Seeding: Bidirectional Flow of Tumor Cells
Microbes, Microbiota, and Colon Cancer
Yibin Kang, Klaus Pantel  Cancer Cell 
Frances Balkwill, Kellie A. Charles, Alberto Mantovani  Cancer Cell 
An Integrin-Linked Machinery of Cytoskeletal Regulation that Enables Experimental Tumor Initiation and Metastatic Colonization  Tsukasa Shibue, Mary W.
Jürgen C. Becker, David Schrama  Journal of Investigative Dermatology 
Shifting the Evolving CAR T Cell Platform into Higher Gear
Cancer Stem Cells: Current Status and Evolving Complexities
Volume 22, Issue 2, Pages (August 2012)
Volume 14, Issue 4, Pages (October 2008)
Characteristics and Significance of the Pre-metastatic Niche
The Heterocellular Emergence of Colorectal Cancer
Natural Killer T Cells: An Unconventional T-Cell Subset with Diverse Effector and Regulatory Functions  Anna Balato, Derya Unutmaz, Anthony A. Gaspari 
Pregnancy and breast cancer: The other side of the coin
Releasing the Brakes on Cancer Immunotherapy
Mesenchymal Stromal Cells: New Directions
GATA-3 Function in Innate and Adaptive Immunity
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?
Searching for leukemia stem cells—Not yet the end of the road?
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Volume 12, Issue 6, Pages (December 2007)
Long Noncoding RNAs in Cancer Pathways
The AML Salad Bowl Cancer Cell
Stems Cells and the Pathways to Aging and Cancer
Presentation transcript:

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment  Douglas Hanahan, Lisa M. Coussens  Cancer Cell  Volume 21, Issue 3, Pages 309-322 (March 2012) DOI: 10.1016/j.ccr.2012.02.022 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 Multifactoral Contributions of Activated/Recruited Stromal Calls to the Hallmarks of Cancer Of the eight acquired hallmark capabilities—six core and two emerging (Hanahan and Weinberg, 2011)—seven demonstrably involve contributions by stromal cells of the tumor microenvironment. The stromal cells can be divided into three general classes, depicted here by their involvement in particular hallmarks, illustrating the diversity of their functional contributions. Notably, the importance of each of these stromal cell classes varies with tumor type and organ, governed by parameters of the distinctive tumor microenvironments and underlying oncogenetic alterations in cancer cells and cancer stem cells that arise in primary tumors, and their invasive and metastatic colonizations. Moreover, distinctive cell types and subcell types within these classes can exert variable roles in enabling these capabilities, and in some cases by opposing them, as elaborated in the text and in Figure 2. Cancer Cell 2012 21, 309-322DOI: (10.1016/j.ccr.2012.02.022) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 2 Multiple Stromal Cell Types and Subcell Types of the Tumor Microenvironment Can Variably Contribute to, or in Some Cases Oppose, Acquisition of the Seven Hallmark Functional Capabilities in Different Organ Sites, Tumor Types and Subtypes, and Stages of Progression Major stromal cell subtypes are indicated, along with a synopsis of key functional contributions that such cell subtypes can make. The antagonistic functions of certain subcell types are highlighted in gray. The lists of subtypes and of their key functions are not comprehensive, but rather prominent examples. Not listed are molecular regulatory signals for, and effector agents of, the noted functions. Both lists will certainly be refined in coming years. Also not shown are the crucial cancer cells and cancer stem cells, with which these stromal cells dynamically interact to manifest cancer phenotypes (Hanahan and Weinberg, 2011). Th2, helper type 2; CD4 T cell, CD4-positive lymphocyte; Treg, regulatory T cell; CTL, cytotoxic T lymphocyte; NK/T, natural killer and natural killer T cell; MDSCs, myeloid-derived suppressor cells; αSMA, alpha smooth muscle actin; MSCs, mesenchymal stem cells. Cancer Cell 2012 21, 309-322DOI: (10.1016/j.ccr.2012.02.022) Copyright © 2012 Elsevier Inc. Terms and Conditions